Summary of the technology
beta- carotene as treatment for autism
Project ID : 6-2014-3058
Description of the technology
Amnon AlbeckMD- Hadassah Medical School, Hebrew University, Jerusalem
David Mankuta MD - Department of Obstetrics and Gynaecology, Hadassah Hospital
In vivo proof of concept; ongoing research
Provisional patent application filed
The prevalence of autism is increasing worldwide and is estimated at between 0.5–2.0% (for autism spectrum disorders (ASDs) it is 1 in 68 children in the United States).
·Novel compound administered to the mother during pregnancy or after birth to newborns of families predisposed to "autism" has the potential to prevent /ameliorate autistic symptoms.
·No side Effects in animal models. These results support further clinical studies.
·A novel compound that can be administered to mothers during pregnancy or after birth of newborns in families predisposed to "autism"– it has the potential to prevent /ameliorate autistic symptoms.
·a safe non-teratogenic natural occurring compound that can be consumed safely by human in vivo and in vitro models, both as a preventive and therapeutic drug in animal models of autism.
·When administered to mice this compound reduces significantly restricted and stereotyped behaviours and interests. Moreover it significantly increased social interactions and communication in offspring.
Seeking funding for ongoing research and clinical trial.
An estimated1 in 68 children in the United States develops autism (about 77 million children in USA)
Yosefa Avraham, PhD,Yosefa@md.huji.ac.il +972-2-6757547.Hebrew University Medical School.